John McClean
Overview
Explore the profile of John McClean including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
114
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stack K, Williams N, Calef 3rd F, Sun V, Williford K, Farley K, et al.
Space Sci Rev
. 2021 Feb;
216(8).
PMID: 33568875
The Mars 2020 Perseverance rover landing site is located within Jezero crater, a ∼ 50 km diameter impact crater interpreted to be a Noachian-aged lake basin inside the western edge...
2.
Riggs H, Jalal S, Baghdadi T, Bhatia S, McClean J, Johnson C, et al.
Clin Lung Cancer
. 2012 Oct;
14(3):224-9.
PMID: 23102811
Background: Poor PS is a negative prognostic factor for survival and a risk factor for treatment-related toxicity with standard platinum-doublet chemotherapy for advanced NSCLC. A phase II study combining erlotinib...
3.
Schmitt J, Sommers S, Fisher W, Ansari R, Robin E, Koneru K, et al.
J Thorac Oncol
. 2012 Mar;
7(4):760-3.
PMID: 22425927
The combination of sunitinb (37.5 mg orally daily) + paclitaxel (90 mg/m intravenously on days 1, 8, 15 every 4 weeks) was examined in patients with advanced esophageal or gastroesophageal...
4.
Matei D, Emerson R, Schilder J, Menning N, Baldridge L, Johnson C, et al.
Cancer
. 2008 Jul;
113(4):723-32.
PMID: 18618737
Background: Ovarian tumors frequently express c-Kit and/or platelet-derived growth factor receptors (PDGFRs). Imatinib mesylate blocks the growth of ovarian cancer cells in vitro and may enhance the activity of chemotherapy....
5.
Agarwala A, Fisher W, Bruetman D, McClean J, Taber D, Titzer M, et al.
J Thorac Oncol
. 2008 Apr;
3(4):374-9.
PMID: 18379355
Background: Gefitinib, an inhibitor of the epidermal growth factor receptor (EGFR) pathway, has single agent activity in non-small cell lung cancer (NSCLC). Preclinical studies demonstrate significant interactions between the EGFR...
6.
Navari R, Einhorn L, Loehrer Sr P, Passik S, Vinson J, McClean J, et al.
Support Care Cancer
. 2007 Mar;
15(11):1285.
PMID: 17375339
Objective: The purpose of this study is to determine the control of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC) and highly emetogenic...
7.
Ganjoo K, Robertson M, Fisher W, Jung S, McClean J, Huh S, et al.
Am J Clin Oncol
. 2005 Apr;
28(2):169-72.
PMID: 15803012
Gemcitabine is a pyrimidine analog that is active in patients with aggressive lymphomas and Hodgkin disease. This study assessed tumor response in patients with previously treated follicular or small lymphocytic...